News

Canada-based Portage Biotech holds 54% equity of Biohaven, a privately-held biopharmaceutical firm engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. Catalent’s

A total of 834 patients were included in the trial and were given Keytruda 10mg/kg every three weeks, Keytruda 10mg/kg every two weeks, or four cycles of ipilimumab

According to the company, the combination was generally well tolerated and all patients completed 12 weeks of treatment. The trial evaluated two doses of VX-661 100mg once daily

As part of the deal, Can-Fite will receive an upfront payment of C$1.65m and is eligible for milestone payments of up to C$2m and royalties from product sales

The new cancer therapeutics will be developed using both GenVec’s gene delivery platform and TheraBiologics’ neural stem cell (NSC) technology. Under the deal, GenVec will contribute technology, know-how,

The company’s AAT therapy is being examined in a clinical US Phase I/II trial that is evaluating 24 GvHD patients with inadequate response to steroid treatment following allogeneic

Takeda has licensed exclusive rights to use ImmunoGen’s antibody-drug conjugate (ADC) technology including its new DNA-acting IGN payload agents to develop and commercialize targeted anticancer therapeutics to up

Based in the recently reported nonclinical results, the company intends to start dosing in a Phase II trial of vepoloxamer in patients with chronic heart failure in the

Under the deal, scientists at CSHL and GSK will pursue drug development based on a new approach to regulate the enzymatic activity of the phosphatase PTP1B. The multiyear